Literature DB >> 1854611

The prognostic value of immunoperoxidase staining with monoclonal antibodies NCRC-11 and 3E1.2 in breast cancer.

I M Muir1, R G Reed, S A Stacker, A I Alexander, I F McKenzie, R C Bennett.   

Abstract

The variation in survival of women with clinically similar breast cancers may lead to difficulty in clinical management so it is important to recognise factors which indicate the prognosis. Immunoperoxidase staining patterns of primary breast tumours using monoclonal antibody NCRC-11 have been shown to relate to overall survival (Ellis et al., 1985) but the results have not been reproducible in other centres. In this study paraffin sections of 483 primary breast cancers were stained with NCRC-11 and 3E1.2 using an immunoperoxidase system. The tumour staining patterns were compared with overall survival using life tables and tested for relative prognostic significance by Cox's multivariate analysis. NCRC-11 related to survival in all 483 cases (chi 2 5.8, P = 0.02) but both antibodies achieved maximum prognostic significance in lymph node negative patients (chi 2 9.4, P less than 0.002 and chi 2 10.7, P less than 0.001) in whom no other factor was more significant. Immunoperoxidase staining patterns produced by monoclonal antibodies NCRC-11 and 3E1.2 are important prognostic factors in breast cancer.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1854611      PMCID: PMC1977294          DOI: 10.1038/bjc.1991.254

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  12 in total

1.  Detection of mammary serum antigen in sera from breast cancer patients using monoclonal antibody 3E1.2.

Authors:  S A Stacker; C H Thompson; N P Sacks; J Tjandra; M G Lowe; J Bishop; I F McKenzie
Journal:  Cancer Res       Date:  1988-12-15       Impact factor: 12.701

2.  Survival in breast cancer related to tumour oestrogen receptor status and immunohistochemical staining for NCRC 11.

Authors:  B Angus; J Napier; J Purvis; I O Ellis; R A Hawkins; F Carpenter; C H Horne
Journal:  J Pathol       Date:  1986-08       Impact factor: 7.996

3.  Prognostic factors in breast cancer and the development of a prognostic index.

Authors:  R M Bryan; R J Mercer; R C Bennett; G C Rennie
Journal:  Br J Surg       Date:  1986-04       Impact factor: 6.939

4.  Interobserver reproducibility of histopathological features in stage II breast cancer. An ECOG study.

Authors:  K W Gilchrist; L Kalish; V E Gould; S Hirschl; J E Imbriglia; W M Levy; A S Patchefsky; D W Penner; J Pickren; J A Roth
Journal:  Breast Cancer Res Treat       Date:  1985       Impact factor: 4.872

5.  A new breast carcinoma antigen defined by a monoclonal antibody.

Authors:  S A Stacker; C Thompson; C Riglar; I F McKenzie
Journal:  J Natl Cancer Inst       Date:  1985-11       Impact factor: 13.506

6.  A monoclonal antibody, NCRC-11, raised to human breast carcinoma. 1. Production and immunohistological characterization.

Authors:  I O Ellis; R A Robins; C W Elston; R W Blamey; B Ferry; R W Baldwin
Journal:  Histopathology       Date:  1984-05       Impact factor: 5.087

7.  Immunocytochemical staining of breast carcinoma with the monoclonal antibody NCRC 11: a new prognostic indicator.

Authors:  I O Ellis; C P Hinton; J MacNay; C W Elston; A Robins; A A Owainati; R W Blamey; R W Baldwin; B Ferry
Journal:  Br Med J (Clin Res Ed)       Date:  1985-03-23

8.  Purification and biochemical characterisation of a novel breast carcinoma associated mucin-like glycoprotein defined by antibody 3E1.2.

Authors:  S A Stacker; J J Tjandra; P X Xing; I D Walker; C H Thompson; I F McKenzie
Journal:  Br J Cancer       Date:  1989-04       Impact factor: 7.640

9.  Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years.

Authors:  H J BLOOM; W W RICHARDSON
Journal:  Br J Cancer       Date:  1957-09       Impact factor: 7.640

10.  Evaluation of immunoreactivity with monoclonal antibody NCRC 11 in breast carcinoma.

Authors:  I O Ellis; J Bell; J M Todd; M Williams; C Dowle; A R Robins; C W Elston; R W Blamey; R W Baldwin
Journal:  Br J Cancer       Date:  1987-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.